Ranking: Baxter, J&J lead green pharma companies

Baxter ($BAX) leads public-company drugmakers in Newsweek's annual top 500 global sustainability ratings. Finishing in the 24th spot, it edged out Johnson & Johnson ($JNJ) in 26th place and Novartis ($NVS) in 34th.

To rank companies, Newsweek considers their environmental footprint, green management initiatives and sustainability communications.

AstraZeneca ($AZN), 62nd, and Novo Nordisk ($NVO), 72nd, round out drugmakers in the top 100.

Roche ($RHHBY) and Pfizer ($PFE) finished next among big pharma, at 103rd and 106th, respectively. Bayer ($BAY), Sanofi ($SNY), Bristol-Myers Squibb ($BMY), Eli Lilly ($LLY), Merck KGaA, GlaxoSmithKline ($GSK), Merck U.S. ($MRK), Abbott ($ABT) and Teva ($TEVA) all finished in the top 500.

Among its overall findings: Momentum behind green initiatives has "seriously stalled, at least in the public sector," largely due to the economy.

- see the ranking
- here's the story

Special Report: The 12 greenest companies in biopharma

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.